Morphologic and molecular heterogeneity in imatinib-resistant GIST

被引：0
|
作者：
Liegl, B.
Kepten, I.
Donsky, R.
Fletcher, C. D. M.
Corless, C. L.
Fletcher, J. A.
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Med Univ Graz, Graz, Austria
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
51
引用
收藏
页码：14A / 14A
页数：1
相关论文
共 50 条
  • [41] Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib
    Ikezoe, Takayuki
    Togitani, Kazuto
    Tasaka, Taizo
    Nishioka, Chie
    Yokoyama, Akihito
    LEUKEMIA RESEARCH, 2010, 34 (08) : E200 - E201
  • [42] A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib
    Yandim, Melis Kartal
    Ceylan, Cagatay
    Elmas, Efe
    Baran, Yusuf
    TUMOR BIOLOGY, 2016, 37 (02) : 2365 - 2378
  • [43] Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines
    Deguchi, Yasuyuki
    Kimura, Shinya
    Ashihara, Eishi
    Niwa, Tomoko
    Hodohara, Keiko
    Fujiyama, Yoshihide
    Maekawa, Taira
    LEUKEMIA RESEARCH, 2008, 32 (06) : 980 - 983
  • [44] Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST
    Hohenberger, P.
    Bauer, S.
    Gruenwald, V.
    Hartmann, J. T.
    Jaeger, E.
    Ottmann, O. G.
    Hosius, C.
    May, C.
    Pustowka, A.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial
    Schardt, L. A.
    Serrano, C.
    Trent, J. C.
    Krzeciesa, D.
    Newberry, K.
    Grassian, A.
    Kang, Y-K.
    Rutkowski, P.
    Jones, R. L.
    Heinrich, M.
    Tap, W. D.
    Pantaleo, M. A.
    von Mehren, M.
    Fletcher, B. S.
    Muehlenberg, T.
    George, S.
    Mir, O.
    Bauer, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1050 - S1051
  • [46] Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors
    Liu, Wei Zhen
    Du, Yu Qiang
    Shen, Qian
    Tao, Kai Xiong
    Zhang, Peng
    JOURNAL OF DIGESTIVE DISEASES, 2023,
  • [47] Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors
    Cao, Lei
    Zheng, Kunming
    Liu, Yanhong
    Song, Peng
    Wang, Chuntao
    Wang, Hongzhi
    Wang, Nan
    Zhang, Shiwu
    Zhao, Yongjie
    FRONTIERS IN GENETICS, 2022, 13
  • [48] An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
    Agarwal, A.
    Eide, C. A.
    Harlow, A.
    Corbin, A. S.
    Mauro, M. J.
    Druker, B. J.
    Corless, C. L.
    Heinrich, M. C.
    Deininger, M. W.
    LEUKEMIA, 2008, 22 (12) : 2269 - 2272
  • [49] Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
    Boichuk, Sergei
    Dunaev, Pavel
    Skripova, Vera
    Galembikova, Aigul
    Bikinieva, Firyuza
    Shagimardanova, Elena
    Gazizova, Guzel
    Deviatiiarov, Ruslan
    Valeeva, Elena
    Mikheeva, Ekaterina
    Vasilyeva, Maria
    Kopnin, Pavel
    Strelnikov, Vladimir
    Kiyamova, Ramziya
    CANCERS, 2023, 15 (22)
  • [50] A patient derived xenograft (PDX) platform for development of next generation KIT kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors (GIST)
    Mullins, Chelsea
    Ricono, Jill
    Carson, Patrick
    Habets, Gaston
    Shellooe, Rafe
    Hoa Nguyen
    Broudy, Thomas
    Mirsaidi, Cyrus
    Nair, Praveen
    CANCER RESEARCH, 2014, 74 (19)
12345